Polaryx Therapeutics, Inc. (PLYX) Income Statement
PLYX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsPLYX revenue and net income
PLYX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
PLYX quarterly EPS vs estimates
Polaryx Therapeutics beat the analyst EPS estimate in 1 of the last 3 quarters. Next report: November 12, 2026 (estimate $-0.06).
PLYX income statement
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Research & development | $6.3M | $2.8M | $2.8M |
| Sales, general & admin | $1.6M | $1.5M | $1.0M |
| Total operating expenses | $7.8M | $4.4M | $3.8M |
| Operating income | −$7.8M | −$4.4M | −$3.8M |
| Income before taxes | −$9.0M | −$30.4M | −$3.8M |
| Net income | −$9.0M | −$30.4M | −$3.8M |
| EBITDA | −$9.0M | −$30.4M | −$3.8M |
| EPS (diluted) | −$0.16 | −$0.16 | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research & development | $719,000 | $679,000 | $560,000 | $514,000 | $476,000 | $4.7M | $350,000 | $354,000 |
| Sales, general & admin | $661,000 | $1.3M | $351,000 | $460,000 | $408,000 | $336,000 | $373,000 | $417,000 |
| Total operating expenses | $1.4M | $2.0M | $911,000 | $974,000 | $884,000 | $5.1M | $723,000 | $771,000 |
| Operating income | −$1.4M | −$2.0M | −$911,000 | −$974,000 | −$884,000 | −$5.1M | −$723,000 | −$771,000 |
| Income before taxes | −$1.4M | −$2.5M | −$1.5M | −$1.4M | −$1.0M | −$5.1M | −$723,000 | −$771,000 |
| Net income | −$1.4M | −$2.5M | −$1.5M | −$1.4M | −$1.0M | −$5.1M | −$723,000 | −$771,000 |
| EBITDA | −$1.4M | −$2.5M | −$1.5M | −$1.4M | −$1.0M | −$5.1M | −$723,000 | −$771,000 |
| EPS (diluted) | −$0.03 | −$0.05 | −$0.16 | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in PLYX's financial statements (latest annual report filed December 31, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
PLYX financial results
Polaryx Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $9.0 million. Diluted earnings per share came to −$0.16.
See the PLYX stock overview for the latest quote and news, or the PLYX chart for price history and technical indicators.
PLYX income statement FAQ
Does Polaryx Therapeutics have revenue?
Polaryx Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Polaryx Therapeutics profitable?
No. Polaryx Therapeutics reported a net loss of $9.0 million in fiscal 2025.
How much does Polaryx Therapeutics spend on research and development?
Polaryx Therapeutics spent $6.3 million on research and development in fiscal 2025.
What are Polaryx Therapeutics's earnings per share?
Polaryx Therapeutics earned $-0.16 per diluted share in fiscal 2025, compared with $-0.16 a year earlier.
When will Polaryx Therapeutics report its next earnings?
Polaryx Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 12, 2026.
When does Polaryx Therapeutics's fiscal year end?
Polaryx Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on December 31, 2025.